# EDGAR Filing Document

**Accession Number:** 0001699737
**File Stem:** 0001104659-23-021880
**Filing Date:** 2023-2
**Character Count:** 14580
**Document Hash:** 34490ffd18465a24d68b909050dfdde7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-021880.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001104659-23-021880

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**GROUP MEMBERS**: SAMSARA BIOCAPITAL GP, LLC

**GROUP MEMBERS**: SRINIVAS AKKARAJU, MD, PHD

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nkarta, Inc.
- **CENTRAL INDEX KEY:** 0001787400
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474515206
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91570
- **FILM NUMBER:** 23631047

**BUSINESS ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT
- **STREET 2:** SUITE 102
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-582-4923

**MAIL ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT
- **STREET 2:** SUITE 102
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Samsara BioCapital, L.P.
- **CENTRAL INDEX KEY:** 0001699737
- **IRS NUMBER:** 813958301
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 285-4270

**MAIL ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

Nkarta, Inc.

(Name of Issuer)

**Common Stock, $0.0001 par value per share**

(Title of Class of Securities)

**65487U 108** 

(CUSIP Number)

**Miran Ahmad**

**Chief Financial Officer**

**Samsara BioCapital GP, LLC**

**628 Middlefield Road**

**Palo Alto, CA 94301**

**(650) 285-4270**

(Name, Address and Telephone Number of Person<br> Authorized to Receive Notices and Communications)

**April 28, 2022**

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ◻

**Note**: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1. Name of Reporting Persons<br>
Samsara BioCapital, L.P.

2. Check the Appropriate Box if a Member of a Group (see instructions)

(a) ◻

(b) ⌧ (1)

3. SEC USE ONLY

4. Source of Funds (see instructions) WC

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
 2(d) or 2(e) ◻

6. Citizenship or Place of Organization Delaware

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;7. | &nbsp;&nbsp; Sole Voting Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;8. | &nbsp;&nbsp; Shared Voting Power<br>2,868,035 shares (2) |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;9. | &nbsp;&nbsp; Sole Dispositive Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;10. | &nbsp;&nbsp; Shared Dispositive Power<br>2,868,035 shares (2) |

---

11. Aggregate Amount Beneficially Owned by Each Reporting
 Person 2,868,035 shares (2)

12. Check if the Aggregate Amount in Row (11) Excludes
 Certain Shares (see instructions) ◻

13. Percent of Class Represented by Amount in Row
 11 5.9% (3)

14. Type of Reporting Person (see instructions) PN

---

| | |
|:---|:---|
| <sup>1</sup> |  |
| <sup>2</sup> | Samsara LP is the record owner of 2,868,035 shares of Common Stock ("Samsara LP Shares"). As the sole general partner of Samsara LP, Samsara GP may be deemed to own beneficially the Samsara LP Shares. As a managing member of Samsara GP, the Managing General Partner also may be deemed to own beneficially the Samsara LP Shares.<br>|
| <sup>3</sup> | The percentage of the class is determined in accordance with Rule 13d-3 under the Exchange Act, based on the 48,813,720 shares of Common Stock outstanding of Nkarta, Inc. (the "Issuer") as of November 7, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission ("SEC") on November 9, 2022. |

---

1. Name of Reporting Persons<br>
Samsara BioCapital GP, LLC

2. Check the Appropriate Box if a Member of a Group (see instructions)

(a) ◻

(b) ⌧ (1)

3. SEC USE ONLY

4. Source of Funds (see instructions) AF

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
 2(d) or 2(e) ◻

6. Citizenship or Place of Organization Delaware

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;7. | &nbsp;&nbsp; Sole Voting Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;8. | &nbsp;&nbsp; Shared Voting Power<br>2,868,035 shares (2) |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;9. | &nbsp;&nbsp; Sole Dispositive Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;10. | &nbsp;&nbsp; Shared Dispositive Power<br>2,868,035 shares (2) |

---

11. Aggregate Amount Beneficially Owned by Each Reporting
 Person 2,868,035 shares (2)

12. Check if the Aggregate Amount in Row (11) Excludes
 Certain Shares (see instructions) ◻

13. Percent of Class Represented by Amount in Row
 11 5.9% (3)

14. Type of Reporting Person (see instructions) OO

---

| | |
|:---|:---|
| <sup>1</sup> | This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.<br>|
| <sup>2</sup> | Samsara LP is the record owner of 2,868,035 shares of Common Stock ("Samsara LP Shares"). As the sole general partner of Samsara LP, Samsara GP may be deemed to own beneficially the Samsara LP Shares. As a managing member of Samsara GP, the Managing General Partner also may be deemed to own beneficially the Samsara LP Shares.<br>|
| <sup>3</sup> | The percentage of the class is determined in accordance with Rule 13d-3 under the Exchange Act, based on the 48,813,720 shares of Common Stock outstanding of Nkarta, Inc. (the "Issuer") as of November 7, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission ("SEC") on November 9, 2022. |

---

1. Name of Reporting Persons<br>
Srinivas Akkaraju, MD, PhD

2. Check the Appropriate Box if a Member of a Group (see instructions)

(a) ◻

(b) ⌧ (1)

3. SEC USE ONLY

4. Source of Funds (see instructions) AF

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
 2(d) or 2(e) ◻

6. Citizenship or Place of Organization United States

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;7. | &nbsp;&nbsp; Sole Voting Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;8. | &nbsp;&nbsp; Shared Voting Power<br>2,868,035 shares (2) |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;9. | &nbsp;&nbsp; Sole Dispositive Power<br>0 shares |
| &nbsp;&nbsp;&nbsp;&nbsp; Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | &nbsp;&nbsp;10. | &nbsp;&nbsp; Shared Dispositive Power<br>2,868,035 shares (2) |

---

11. Aggregate Amount Beneficially Owned by Each Reporting
 Person 2,868,035 shares (2)

12. Check if the Aggregate Amount in Row (11) Excludes
 Certain Shares (see instructions) ◻

13. Percent of Class Represented by Amount in Row
 11 5.9% (3)

14. Type of Reporting Person (see instructions) IN

---

| | |
|:---|:---|
| <sup>1</sup> | This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.<br>|
| <sup>2</sup> | Samsara LP is the record owner of 2,868,035 shares of Common Stock ("Samsara LP Shares"). As the sole general partner of Samsara LP, Samsara GP may be deemed to own beneficially the Samsara LP Shares. As a managing member of Samsara GP, the Managing General Partner also may be deemed to own beneficially the Samsara LP Shares.<br>|
| <sup>3</sup> | The percentage of the class is determined in accordance with Rule 13d-3 under the Exchange Act, based on the 48,813,720 shares of Common Stock outstanding of Nkarta, Inc. (the "Issuer") as of November 7, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission ("SEC") on November 9, 2022. |

---

**Explanatory Note**

This Amendment No. 1 (the "Amendment"), which amends the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 22, 2020 (the "Original Schedule 13D") relates to the Common Stock of Nkarta, Inc. (the "Issuer"), as a result of the Samsara LP's purchase of shares of Common Stock in a public offering by the Issuer in April 2022.

Items 3 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

**Item 3. Source and Amount of Funds or Other Consideration.** 

*Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 3:*

On April 28, 2022, Samsara LP purchased 833,333 shares of Common Stock from the underwriters of a public offering of the Issuer's common stock at a price of $15.00 per share, for an aggregate purchase price of $12.5 million.

As of the date hereof, each of the Reporting Persons may be deemed to beneficially own 2,868,035 shares of Common Stock.

The funds used by the Reporting Entities to acquire the Samsara LP Shares described herein was from working capital.

**Item 5.** **Interest in Securities of the Issuer** 

*Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:*

(a) – (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of February 14, 2022:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Persons** | **Shares Held<br> Directly** | **Sole Voting<br> Power** | **Shared <br> Voting Power** | **Sole<br> Dispositive<br> Power** | **Shared<br> Dispositive<br> Power** | **Beneficial<br> Ownership** | **Percentage of<br> Class (2)** |
| Samsara LP (1) | 2868035 | 0 | 2868035 | 0 | 2868035 | 2868035 | 5.9% |
| Samsara GP (1) | 0 | 0 | 2868035 | 0 | 2868035 | 2868035 | 5.9% |
| Managing GP (1) | 0 | 0 | 2868035 | 0 | 2868035 | 2868035 | 5.9% |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Samsara LP is the record owner of 2,868,035 shares of Common Stock ("Samsara LP Shares").
As the sole general partner of Samsara LP, Samsara GP may be deemed to own beneficially the Samsara LP Shares. As a managing member of
Samsara GP, the Managing General Partner may also be deemed to own beneficially the Samsara LP Shares.

(2) The percentage
of the class is determined in accordance with Rule 13d-3 under the Exchange Act, based on the 48,813,720 shares of Common Stock outstanding
of Nkarta, Inc. (the "Issuer") as of November 7, 2022, as set forth in the Issuer's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2022 filed with the Securities and Exchange Commission ("SEC") on November 9, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;(c) None of the Reporting Persons has effected any transactions in shares of the Issuer's Common Stock
during the last 60 days.

&nbsp;&nbsp;&nbsp;&nbsp;(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from,
or any proceeds from the sale of, share beneficially owned by any of the Reporting Persons.

&nbsp;&nbsp;&nbsp;&nbsp;(e) Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| **SAMSARA BIOCAPITAL, L.P.**<br> **By: Samsara BioCapital GP, LLC**<br> **Its: General Partner** | **SAMSARA BIOCAPITAL, L.P.**<br> **By: Samsara BioCapital GP, LLC**<br> **Its: General Partner** |
| By: | /s/ Srinivas Akkaraju |
| Srinivas Akkaraju | Srinivas Akkaraju |
| Managing Member | Managing Member |
| **SAMSARA BIOCAPITAL GP, LLC** | **SAMSARA BIOCAPITAL GP, LLC** |
| By: | /s/ Srinivas Akkaraju |
| Srinivas Akkaraju | Srinivas Akkaraju |
| Managing Member | Managing Member |
| **SRINIVAS AKKARAJU** | **SRINIVAS AKKARAJU** |
| /s/ Srinivas Akkaraju | /s/ Srinivas Akkaraju |

---